New partnership opportunities
Seeking Collaborative Partners to Advance Human Genomic Discoveries in Health and Disease Regeneron Genetics Center® is seeking collaborators that have assembled deep, well-characterized human subject cohorts for specific diseases. The focus is on accessing human biospecimens appropriately consented for genetic sequencing. Submission deadline: June 29, 2026. → Download PDF→ Respond to this campaign
Good AI Practice in drug development
2026 January 14 The US Food and Drug Administration (FDA) has collaborated with the European Medicines Agency (EMA) to develop 10 guiding principles of good AI practice in drug development that industry and product developers can consider when using artificial intelligence (AI) to advance the development of drugs and biological products.
LEADING IN GOLD STANDARD SCIENCE: An NIH Implementation Plan
August 22, 2025 Leading in Gold Standard Science: This implementation plan outlines NIH’s key accomplishments to date in delivering gold standard science to the American public and presents a transparent vision for the road ahead. The Plan builds upon NIH’s longstanding commitment to scientific integrity and incorporates the nine, interlocking tenets of gold standard science […]
White House Unveils America’s AI Action Plan
2025-January 23 The White House today released “Winning the AI Race: America’s AI Action Plan”, in accordance with President Trump’s January executive order on Removing Barriers to American Leadership in AI. Winning the AI race will usher in a new golden age of human flourishing, economic competitiveness, and national security for the American people. The Plan […]
Institutional Review Board (IRB) Written Procedures: Guidance for Institutions and IRBs
Institutional Review Board (IRB) Written Procedures: Guidance for Institutions and IRBs February 2025 This guidance has been prepared jointly by the Department of Health and Human Services (HHS) Office for Human Research Protections (OHRP) and the Food and Drug Administration (FDA). To enhance human subject protection and reduce regulatory burden, OHRP and FDA have been […]